retatrutide type 2 diabetes phase 2 trial ESC 2024: improves lipid and cardiovascular risk profile in II In the Phase 3 TRANSCEND-T2D-1

In the case of Ozempic, this would mean a large group of individuals who have experienced vision problems potentially linked to the medication

Some real world data shows promise that a few may maintain their full weight loss for at least one year after stopping GLP-1 therapy, especially if they continue with lifestyle improvements

While Retatrutide remains investigational, eligible patients may be able to access medical weight loss options that are currently available through provider-supervised programs

Search by status and location: On ClinicalTrials.gov, filter by Status "Recruiting" and your ZIP code to surface only open trials near you